Circulating monocyte subsets in human chronic graft-versus-host disease

Takaaki Konuma1, Chisato Kohara2, Eri Watanabe3

  • 1Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. tkonuma@ims.u-tokyo.ac.jp.

Insights

Chronic graft-versus-host disease (cGVHD) involves monocytes/macrophages. Specific monocyte subset surface marker alterations correlate with organ-specific cGVHD, suggesting potential biomarkers for this condition after hematopoietic cell transplantation.

Area of Science:

  • Immunology
  • Hematology
  • Transplantation Medicine

Background:

  • Chronic graft-versus-host disease (cGVHD) is a significant complication following allogeneic hematopoietic cell transplantation (HCT).
  • Monocytes and macrophages are key players in the inflammatory and fibrotic processes characteristic of cGVHD.
  • Understanding monocyte subset behavior is crucial for managing cGVHD.

Purpose of the Study:

  • To investigate the expression of surface markers on circulating monocyte subsets in patients post-HCT.
  • To determine if these marker expressions correlate with the presence and severity of cGVHD.
  • To identify potential biomarkers for organ-specific cGVHD.

Main Methods:

  • Analysis of monocyte subset populations (classical, non-classical) in 145 patients at least 12 months post-HCT without disease recurrence.
  • Measurement of activation markers, chemokine receptors (e.g., CCR5, CX3CR1), and scavenger receptors (e.g., CD204) on monocytes.
  • Correlation of marker expression levels with clinical manifestations of cGVHD, including joint and lung involvement.

Main Results:

  • No significant differences in monocyte subset numbers or proportions were observed between patients with and without cGVHD.
  • Lower CCR5 expression on classical monocytes was associated with joint cGVHD.
  • Higher CD204 and lower CX3CR1 expression on non-classical monocytes were linked to lung cGVHD.

Conclusions:

  • Alterations in surface markers on circulating monocyte subsets are associated with organ-specific cGVHD development.
  • These specific monocyte surface marker changes may serve as candidate biomarkers for cGVHD.
  • Further research into these monocyte alterations could lead to improved diagnostics and therapeutics for cGVHD.

Related Concept Videos

Chronic Obstructive Pulmonary Disease01:24

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
2.6K
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
762
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
4.7K
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
3.9K
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
3.2K
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
679